Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,943.45 -2,144.55 (-3.40%) CMC Crypto 200
1,259.14 -98.87 (-7.28%)
Arcutis Biotherapeutics, Inc. (ARQT)
After hours:
| Previous close | 8.02 |
| Open | 8.01 |
| Bid | 7.81 x 1700 |
| Ask | 7.86 x 800 |
| Day's range | 7.84 - 8.53 |
| 52-week range | 1.76 - 13.17 |
| Volume | |
| Avg. volume | 3,796,377 |
| Market cap | 905.716M |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.78 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
GlobeNewswireArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees. These awards were approved by the Compensation Committee of Arcuti
- GlobeNewswire
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the cal
Simply Wall St.Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts
Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shareholders will have a reason to smile today, with the analysts making...
